Senate bill · 119th Congress · Latest step: Committee action
Expedited Access to Biosimilars Act
Official title: A bill to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy.
Sponsor: Sen. Rand Paul R-KYWhere it went
- IntroducedApr 10, 2025
- Committee actionJul 22, 2026
- Passed Senate—
- Passed House—
- To the President—
- Became law—
Latest action: Jul 27, 2026 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 520.
Vote results
No recorded roll-call votes on this bill in PORKER’s records (voice votes and unanimous consent are not roll calls; roll-call records start in 2011).
Cosponsors
2 cosponsors — 1 Republican, 1 Democrat
1 of 2 cosponsors (50%) are from the other party.
More from the sponsor
Other 119th Congress bills sponsored by Sen. Rand Paul.
- S. 2733 (119th) Duplication Scoring Act of 2025
- S. 854 (119th) Risky Research Review Act
- S. 855 (119th) Royalty Transparency Act
- S.Res. 29 (119th) An original resolution expressing the sense of the Senate that the President of the United States possesses legal authority under existing…
- S.Res. 77 (119th) An original resolution authorizing expenditures by the Committee on Homeland Security and Governmental Affairs.
- S. 485 (119th) Regulations from the Executive in Need of Scrutiny Act of 2025
Sponsor’s state and district
Data as of Sep 25, 2026 · bill record checked by PORKER from Congress.gov · votes from Senate.gov and the House Clerk. PORKER is non-partisan.